{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:26:47Z","timestamp":1792758407230,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA043337"],"award-info":[{"award-number":["R01DA043337"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K02DA032322"],"award-info":[{"award-number":["K02DA032322"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA041898"],"award-info":[{"award-number":["T32DA041898"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medication treatment for opioid use disorder (OUD) (MOUD; buprenorphine and methadone) reduces opioid use and overdose. Discontinuation of MOUD can quickly lead to relapse, overdose and death. Few persons who initiate MOUD are retained on treatment, thus it is critical to identify factors associated with retention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Evaluated data was from an ongoing prospective cohort study of adults aged 18 or older with DSM-5 moderate to severe OUD seeking MOUD in the community and followed for 6\u00a0months. Participants were considered retained on MOUD through 6\u00a0months if they reported taking MOUD at every study interview without discontinuation. A high dose of MOUD was defined as a methadone dose\u2009&gt;\u200985\u00a0mg or buprenorphine dose\u2009\u2265\u200916\u00a0mg. Multivariable logistic regression was conducted to assess factors associated with 6-month MOUD retention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 118 participants (73% male, 58% white, 36% with HIV) were included. Buprenorphine was initiated by 58% and 42% started methadone. MOUD retention was 49% and 58% among buprenorphine and methadone, respectively, at 6-months. In adjusted models, a high MOUD dose (OR\u2009=\u20094.71, 95% CI 2.05\u201310.84) and higher pain interference (OR\u2009=\u20091.59, 95% CI 1.15\u20132.19) was associated with MOUD retention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adequate dosing of MOUD leads to improved retention on MOUD. Further, persons with high pain interference at baseline had higher odds of retention on MOUD. Both methadone and buprenorphine have analgesic effects, thus those with high pain interference could have dual benefits of MOUD for treating OUD and pain. Interventions should be tailored to improve adequate MOUD dosing to improve retention on MOUD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-022-00299-1","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T05:04:27Z","timestamp":1646629467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community"],"prefix":"10.1186","volume":"17","author":[{"given":"Breanne E.","family":"Biondi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Vander Wyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther F.","family":"Schlossberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6318-1000","authenticated-orcid":false,"given":"Sandra A.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"issue":"2","key":"299_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/NOR.0000000000000521","volume":"38","author":"S Salmond","year":"2019","unstructured":"Salmond S, Allread V. A population health approach to America\u2019s opioid epidemic. Orthop Nurs. 2019;38(2):95\u2013108.","journal-title":"Orthop Nurs"},{"issue":"3","key":"299_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.semperi.2019.01.001","volume":"43","author":"J Lyden","year":"2019","unstructured":"Lyden J, Binswanger IA. The United States opioid epidemic. Semin Perinatol. 2019;43(3):123\u201331.","journal-title":"Semin Perinatol"},{"key":"299_CR3","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7006a4","author":"CL Mattson","year":"2021","unstructured":"Mattson CL. Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019. MMWR Morb Mortal Wkly Rep. 2021. https:\/\/doi.org\/10.15585\/mmwr.mm7006a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"299_CR4","unstructured":"CDC, National Center for Health Statistics. Drug overdose deaths in the US top 100,000 annually. 2021. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2021\/20211117.htm. Accessed 23 Dec 2021."},{"key":"299_CR5","doi-asserted-by":"publisher","DOI":"10.17226\/25310","volume-title":"Medications for opioid use disorder save lives","author":"AI Leshner","year":"2019","unstructured":"Leshner AI, Mancher M. Medications for opioid use disorder save lives. Washington DC: The National Academies Collection Reports funded by National Institutes of Health; 2019."},{"key":"299_CR6","volume-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019","unstructured":"National Academies of Sciences, Engineering, and Medicine. Medications for opioid use disorder save lives. Washington DC: The National Academies Press; 2019."},{"issue":"50 Suppl 3","key":"299_CR7","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1086\/651482","volume":"15","author":"D Vlahov","year":"2010","unstructured":"Vlahov D, Robertson AM, Strathdee SA. Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis. 2010;15(50 Suppl 3):S114-21.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"299_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0740-5472(03)00029-1","volume":"24","author":"KH Wong","year":"2003","unstructured":"Wong KH, Lee SS, Lim WL, Low HK. Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat. 2003;24(3):233\u20139.","journal-title":"J Subst Abuse Treat"},{"key":"299_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz411","author":"BE Biondi","year":"2019","unstructured":"Biondi BE, Frank C, Horn BP, Springer SA. Reduced sexual risk behaviors among persons with HIV after release from the criminal justice system. Open Forum Infect Dis. 2019. https:\/\/doi.org\/10.1093\/ofid\/ofz411.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"299_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/QAI.0000000000000165","volume":"66","author":"GE Woody","year":"2014","unstructured":"Woody GE, Bruce D, Korthuis PT, Chhatre S, Poole S, Hillhouse M, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr. 2014;66(3):288\u201393.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"299_CR11","doi-asserted-by":"publisher","first-page":"e0232086","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS ONE. 2020;15(5):e0232086.","journal-title":"PLoS ONE"},{"issue":"1","key":"299_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22\u201335.","journal-title":"J Addict Dis"},{"key":"299_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsat.2018.08.009","volume":"94","author":"A Lo","year":"2018","unstructured":"Lo A, Kerr T, Hayashi K, Milloy MJ, Nosova E, Liu Y, et al. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs. J Subst Abuse Treat. 2018;94:41\u20136.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"299_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11845-015-1314-5","volume":"185","author":"CD Darker","year":"2016","unstructured":"Darker CD, Ho J, Kelly G, Whiston L, Barry J. Demographic and clinical factors predicting retention in methadone maintenance: results from an Irish cohort. Ir J Med Sci. 2016;185(2):433\u201341.","journal-title":"Ir J Med Sci"},{"issue":"1","key":"299_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction"},{"key":"299_CR16","doi-asserted-by":"publisher","first-page":"108329","DOI":"10.1016\/j.jsat.2021.108329","volume":"126","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Williams AR, Saloner B, Cerd\u00e1 M. Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. J Subst Abuse Treat. 2021;126:108329.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"299_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2006.05.012","volume":"86","author":"SF Greenfield","year":"2007","unstructured":"Greenfield SF, Brooks AJ, Gordon SM, Green CA, Kropp F, McHugh RK, et al. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007;86(1):1\u201321.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"299_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/02791072.2015.1014948","volume":"47","author":"SG Mitchell","year":"2015","unstructured":"Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O\u2019Grady KE, Olsen YK, et al. Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use. J Psychoactive Drugs. 2015;47(2):149\u201357.","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"299_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0740-5472(01)00185-4","volume":"21","author":"PD Friedmann","year":"2001","unstructured":"Friedmann PD, Lemon SC, Stein MD. Transportation and retention in outpatient drug abuse treatment programs. J Subst Abuse Treat. 2001;21(2):97\u2013103.","journal-title":"J Subst Abuse Treat"},{"key":"299_CR20","unstructured":"National Quality Forum. Behavioral Health 2016\u20132017. 2017; p. 118. https:\/\/www.qualityforum.org\/Publications\/2017\/08\/Behavioral_Health_2016-2017_Final_Report.aspx. Accessed 22 Mar 2021."},{"issue":"21","key":"299_CR21","doi-asserted-by":"publisher","first-page":"100704","DOI":"10.1016\/j.conctc.2021.100704","volume":"1","author":"BE Biondi","year":"2021","unstructured":"Biondi BE, Mohanty S, Wyk BV, Montgomery RR, Shaw AC, Springer SA. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemp Clin Trials Commun. 2021;1(21):100704.","journal-title":"Contemp Clin Trials Commun."},{"issue":"Suppl 20","key":"299_CR22","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333.","journal-title":"J Clin Psychiatry"},{"key":"299_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"299_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1017\/S0033291797006399","volume":"28","author":"World Health Organization Quality of Life Group","year":"1998","unstructured":"World Health Organization Quality of Life Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28:351\u2013558.","journal-title":"Psychol Med"},{"key":"299_CR25","volume-title":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): manual for use in primary care","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): manual for use in primary care. Geneva: WHO; 2010."},{"issue":"1","key":"299_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jama.2018.6971","volume":"320","author":"EC Norton","year":"2018","unstructured":"Norton EC, Dowd BE, Maciejewski ML. Odds ratios\u2014current best practice and use. JAMA. 2018;320(1):84.","journal-title":"JAMA"},{"issue":"105","key":"299_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jsat.2019.07.010","volume":"1","author":"A Meinhofer","year":"2019","unstructured":"Meinhofer A, Williams AR, Johnson P, Schackman BR, Bao Y. Prescribing decisions at buprenorphine treatment initiation: do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 2019;1(105):37\u201343.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"299_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1037\/a0025668","volume":"17","author":"K Burlew","year":"2011","unstructured":"Burlew K, Larios S, Suarez-Morales L, Holmes B, Venner K, Chavez R. Increasing ethnic minority participation in substance abuse clinical trials: lessons learned in the National Institute on Drug Abuse\u2019s Clinical Trials Network. Cultur Divers Ethnic Minor Psychol. 2011;17(4):345\u201356.","journal-title":"Cultur Divers Ethnic Minor Psychol"},{"key":"299_CR29","doi-asserted-by":"publisher","DOI":"10.31478\/202004b","author":"BK Madras","year":"2020","unstructured":"Madras BK, Ahmad NJ, Wen J, Sharfstein J, et al. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. 2020. https:\/\/doi.org\/10.31478\/202004b.","journal-title":"NAM Perspect"},{"key":"299_CR30","doi-asserted-by":"publisher","first-page":"108246","DOI":"10.1016\/j.jsat.2020.108246","volume":"123","author":"D Frank","year":"2021","unstructured":"Frank D. A chance to do it better: methadone maintenance treatment in the age of COVID-19. J Subst Abuse Treat. 2021;123:108246.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"299_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","volume":"47","author":"O Amram","year":"2021","unstructured":"Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse. 2021;47(6):722\u20139.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"5","key":"299_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.pec.2016.12.001","volume":"100","author":"J Trujols","year":"2017","unstructured":"Trujols J, Gonz\u00e1lez-Saiz F, Manresa MJ, Alcaraz S, Batlle F, Duran-Sindreu S, et al. Patient perception of methadone dose adequacy in methadone maintenance treatment: the role of perceived participation in dosage decisions. Patient Educ Couns. 2017;100(5):981\u20136.","journal-title":"Patient Educ Couns"},{"issue":"5","key":"299_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/ADM.0b013e318297021e","volume":"7","author":"JJ Sanders","year":"2013","unstructured":"Sanders JJ, Roose RJ, Lubrano MC, Lucan SC. Meaning and methadone: patient perceptions of methadone dose and a model to promote adherence to maintenance treatment. J Addict Med. 2013;7(5):307\u201313.","journal-title":"J Addict Med"},{"issue":"1","key":"299_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/08897077.2015.1088496","volume":"37","author":"AD Fox","year":"2016","unstructured":"Fox AD, Masyukova M, Cunningham CO. Optimizing psychosocial support during office-based buprenorphine treatment in primary care: patients\u2019 experiences and preferences. Subst Abuse. 2016;37(1):70\u20135.","journal-title":"Subst Abuse"},{"issue":"3","key":"299_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/02673037.2015.1080816","volume":"31","author":"JR Woodhall-Melnik","year":"2016","unstructured":"Woodhall-Melnik JR, Dunn JR. A systematic review of outcomes associated with participation in Housing First programs. Hous Stud. 2016;31(3):287\u2013304.","journal-title":"Hous Stud"},{"issue":"3","key":"299_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/10550887.2012.694602","volume":"31","author":"PW Appel","year":"2012","unstructured":"Appel PW, Tsemberis S, Joseph H, Stefancic A, Lambert-Wacey D. Housing first for severely mentally ill homeless methadone patients. J Addict Dis. 2012;31(3):270\u20137.","journal-title":"J Addict Dis"},{"issue":"56","key":"299_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.drugpo.2018.03.012","volume":"1","author":"M Parpouchi","year":"2018","unstructured":"Parpouchi M, Moniruzzaman A, Rezansoff SN, Russolillo A, Somers JM. The effect of Housing First on adherence to methadone maintenance treatment. Int J Drug Policy. 2018;1(56):73\u201380.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"299_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/oxfordjournals.schbul.a033351","volume":"24","author":"RE Drake","year":"1998","unstructured":"Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull. 1998;24(4):589\u2013608.","journal-title":"Schizophr Bull"},{"key":"299_CR39","volume-title":"Medicaid and federal grant funding can improve treatment and housing options for people with substance use disorders","author":"P Bailey","year":"2018","unstructured":"Bailey P. Medicaid and federal grant funding can improve treatment and housing options for people with substance use disorders. Washington, DC: Center on Budget and Policy Priorities; 2018."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00299-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00299-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00299-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T05:04:49Z","timestamp":1646629489000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00299-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00299-1","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study and procedures were approved by the Yale University IRB. Participants provided written and informed consent prior to study entry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript for submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S. Springer has provided paid consultation to Alkermes Inc. for scientific expertise and has received in-kind study drug donations from Alkermes Inc. and Indivior pharmaceutical company for NIH-funded studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}